CRAIG STEVEN GLAZER MD
Prescription History 1497714521
Internal Medicine - Pulmonary Disease in Dallas, TX


Quality Rating: 74.59 out of 100 score

NPI Status: Active since March 18, 2006

Contact Information

5323 HARRY HINES BLVD
DALLAS, TX
ZIP 75390
Phone: (214) 645-2867
Fax: (214) 648-2575

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CRAIG STEVEN GLAZER MD, an active Pulmonary Disease specialist practicing in Dallas, TX. Our medical registry currently tracks 19 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 561 documented patient claims. Among these therapy options, the most frequently utilized medication is Ofev, which accounts for 89 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
TX State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply845
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,166.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$597.22

State Avg Cost Per Claim

$554.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 51.8
Days Supply 1,362
TX State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills65.6
Peer Average Days Supply1,666
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,381.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.69

State Avg Cost Per Claim

$49.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills40.2
Peer Average Days Supply1,200
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,501.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$464.43

State Avg Cost Per Claim

$621.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.2
Peer Average Days Supply929
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,792.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$232.73

State Avg Cost Per Claim

$294.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.0
Days Supply 501
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply287
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $197.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.07

State Avg Cost Per Claim

$9.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 59.0
Days Supply 1,770
TX State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills45.4
Peer Average Days Supply1,350
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.4% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,563.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$522.63

State Avg Cost Per Claim

$543.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills19.8
Peer Average Days Supply586
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,045.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$337.10

State Avg Cost Per Claim

$400.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Esbriet

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply695
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115,537.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,628.14

State Avg Cost Per Claim

$10,679.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 28.0
Days Supply 840
TX State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills96.3
Peer Average Days Supply2,877
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.8% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $137.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.43

State Avg Cost Per Claim

$18.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
TX State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply932
Conservative Utilization

This provider writes prescriptions for this formulation 36.0% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,160.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$385.05

State Avg Cost Per Claim

$460.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.5
Days Supply 575
TX State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills49.2
Peer Average Days Supply1,303
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,021.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.58

State Avg Cost Per Claim

$48.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 60.0
Days Supply 1,800
TX State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills156.5
Peer Average Days Supply4,670
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $302.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.64

State Avg Cost Per Claim

$18.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 82.5
Days Supply 2,460
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,548
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.3% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,226.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$144.79

State Avg Cost Per Claim

$152.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 89
30-Day Fills 89.0
Days Supply 2,670
TX State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills41.2
Peer Average Days Supply1,232
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 122.5% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,176,191.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,215.63

State Avg Cost Per Claim

$12,615.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 1,170
TX State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.4
Peer Average Days Supply638
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $126,667.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,247.88

State Avg Cost Per Claim

$6,318.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 62.0
Days Supply 1,640
TX State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills57.7
Peer Average Days Supply1,050
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $150.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.21

State Avg Cost Per Claim

$5.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 50.6
Days Supply 1,502
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.4
Peer Average Days Supply411
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $168.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.35

State Avg Cost Per Claim

$6.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 70
30-Day Fills 96.0
Days Supply 2,880
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills43.9
Peer Average Days Supply1,317
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 133.3% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $37,795.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$539.93

State Avg Cost Per Claim

$550.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 27.0
Days Supply 810
TX State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills72.8
Peer Average Days Supply2,180
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.5% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,074.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$951.27

State Avg Cost Per Claim

$853.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CRAIG STEVEN GLAZER MD provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.